Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.

Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02527577

Acronym

BLOC-TAP

Enrollment

Registered

2015-08-19

Start date

2010-04-30

Completion date

2015-02-28

Last updated

2015-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer, Adult

Brief summary

The indications liver cancer surgery currently booming due to the increase in surgical techniques and instruments for a more secure resection of liver tissue with a significant reduction in bleeding or surgical complications. This allowed to expand surgical indications in the most fragile patients so assuming optimized anesthetic care. So far, the technique of analgesia reference to this surgery remains administration of morphine analgesia via a device controlled by the patient (PCA) for epidural analgesia is against-indicated because of induced bleeding disorders by surgery. Rafi then McDonnell in 2007 have described a new technique of loco regional anesthesia, the abdomen of the Transversus Abdominis Plane (TAP) nerve block(TAP), which allows selective anesthesia of the abdominal wall. But parietal pain related muscular and nervous sagging surgical approach represent a significant share of post operative pain. This study proposes an evaluation of the abdomen transverse blocks in hepatectomy.

Interventions

DRUGRopivacaIne chlorhydrate

3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48

DRUGPlacebo

injection Hour (H) 0, H12 ; H24, H36 ; H48

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* hepatectomy or segmentectomy

Exclusion criteria

* Sepsis uncontrolled current * Overdose in anticoagulant during general anesthesia * Thrombocytopenia \<50 g / dl * Severe renal impairment: Cockcroft \<30 ml / min * history of ventricular arrhythmia serious unexplained .\* * Allergy to local anesthetics of the amide * Contraindication to remifentanil and morphine * Hypovolemia

Design outcomes

Primary

Measure	Time frame
consumption of morphine over the first 48 hours postoperative.	at 48 hours postoperative

Secondary

Measure	Time frame
pharmacokinetic of ropivacaine (plasma concentrations)	1, 2, 3, 6, 10, 24, 36, 48 hours post-dose

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026